(lp0
S'Maxim Analyst Comments on Cytori Therapeutics Inc Following Azaya Acquisition Smarter Analyst - Jan 19, 2017 Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc  with a price target of $6.00, after the drug developer announced the acquisitions of Azaya Therapeutics for its proprietary liposomal nanoparticle&nbsp;...Cytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya ... - MarketWatchCytori Therapeutics  to Acquire Assets from Privately Held Azaya ... - StreetInsider.com'
p1
aS'The Cytori Therapeutics Inc  Downgraded by Zacks Investment Research to Sell Petro Global News 24 - Mar 21, 2017 Zacks Investment Research lowered shares of Cytori Therapeutics Inc  from a hold rating to a sell rating in a research note issued to investors on Monday morning.Cytori Therapeutics Inc  Stock Rating Lowered by Zacks Investment Research - Chaffey BreezeNews Impact Score Of Cytori Therapeutics Inc  At 100 - Stock Observer'
p2
aS'Stock Update : Cytori Therapeutics Inc Announces Increase of ... Smarter Analyst - Sep 19, 2016 Cytori Therapeutics Inc  announced that the Company and Biomedical Advanced Research and Development Authority , a division of the U.S.'
p3
aS'Cytori Therapeutics Inc  Downgraded by Zacks Investment Research to Sell The Cerbat Gem - Mar 21, 2017 Cytori Therapeutics Inc logo Zacks Investment Research cut shares of Cytori Therapeutics Inc  from a hold rating to a sell rating in a report published on Monday.The Cytori Therapeutics Inc  Lowered to Sell at Zacks Investment Research - Petro Global News 24'
p4
aS'Stock Update : Cytori Therapeutics Inc Partner Kerastem Completes ... Smarter Analyst - Sep 26, 2016 Cytori Therapeutics Inc  announced that its licensee Kerastem Technologies, LLC, has completed enrollment of STYLE, a US phase II clinical trial investigating early stage female and male pattern hair loss.'
p5
aS'Chart Watch: Following Indicators on Shares of Cytori Therapeutics Inc  Midway Monitor - 9 hours ago Investors and Traders continue to monitor technical levels of shares of Cytori Therapeutics Inc . A frequently used tool among technical stock analysts is the moving average.Company Watch: Viewing Levels for Cytori Therapeutics Inc  - Rives Journal'
p6
aS"Cytori Therapeutics'  CEO Marc Hedrick on Q1 2016 Results - Earnings ... Seeking Alpha - May 11, 2016 Second, management feels that the combination of the forecasted spend and revenue may be sufficient to get the Company to the point of breakeven by 2018.Stock Update : Cytori Therapeutics Inc Granted Broad European ... - Smarter Analyst"
p7
aS'Cytori Therapeutics Inc.: Cytori Completes Acquisition of Azaya Therapeutics ... The Wall Street Transcript - Feb 15, 2017 15, 2017  -- Cytori Therapeutics, Inc.  today announced it has completed its acquisition of assets of privately held Azaya Therapeutics, Inc., a leader in the research, development and manufacturing of nanoparticle&nbsp;...Cytori Therapeutics, Inc.  PT Raised to $10 at Maxim Group on Closure of ... - StreetInsider.comCytori Therapeutics  Stock: Gaining On Price Target Increase - CNA Finance '
p8
aS"Maxim's Biotech Insights: Cytori Therapeutics Inc , StemCells Inc  Smarter Analyst - Mar 28, 2016 Recent developments in biotech stocks Cytori Therapeutics Inc  and StemCells Inc  attract analysts' attention as pipeline treatments inch toward the end of their final testing phases."
p9
aS"BARDA Increases Cytori Therapeutics' Contract Option  Investopedia - Sep 23, 2016 recently announced that the Biomedical Advanced Research and Development Authority , a division of the U.S. Department of Health and Human Services , has increased the valuation of an existing option contract related to the company's&nbsp;..."
p10
a.